Rare disease news

FDA approvals, research breakthroughs, clinical trials, and advocacy updates

Curated and summarized by AI for patients and caregivers

🔍
AllDrug approvalsClinical trialsResearchGrants & fundingAdvocacy & policyPipeline
Show:All newsBreaking onlyImportant & breaking
Date:7 days30 days90 daysAll time

4 articles from the last 30 days matching "Parkinson Disease"

Clinical trialRSSToday

Final patient vist done in trial testing Celeste light therapy for Parkinson’s

A company called Photopharmics has finished testing a light therapy device called Celeste for Parkinson's disease. The last patient in the large study has completed all their visits. This is an important step toward potentially getting the device approved for patients to use.

WHY IT MATTERSCompletion of this pivotal trial means Celeste light therapy could move closer to FDA approval, potentially offering Parkinson's patients a new non-drug treatment option if results are positive.
👁 Watch this spaceParkinson's disease
Clinical trialRSS2 days ago

Patient visits wrap up in Parkinson’s trial of oral bezisterim therapy

A company called Biovie has finished enrolling patients in a study testing a new oral medication called bezisterim for early-stage Parkinson's disease. The medication is being tested as a standalone treatment that patients could take by mouth. The researchers will now analyze all the data collected, with results expected later this year.

WHY IT MATTERSIf bezisterim proves effective in this Phase 2 trial, it could offer Parkinson's patients a new oral treatment option that works alone without requiring combination with other medications.
👁 Watch this spaceParkinson's disease
Clinical trialRSSMay 15

Phase 3 trial of solengepras for Parkinson’s disease now fully enrolled

A large clinical trial testing a new Parkinson's disease medication called solengepras has finished enrolling 341 patients. This medication works differently than standard Parkinson's drugs and is being tested alongside regular treatments to see if it helps patients who experience movement problems that come and go throughout the day.

WHY IT MATTERSIf solengepras proves effective in this Phase 3 trial, it could offer Parkinson's patients a new treatment option that works through a different mechanism than current dopamine-based therapies, potentially helping those with motor fluctuations who don't respond adequately to standard medications alone.
👁 Watch this spaceParkinson's disease
Clinical trialRSSApr 24

AAN 2026: Tavapadon helps delay levodopa start in early Parkinson’s

A new experimental drug called tavapadon from AbbVie helped people with early Parkinson's disease delay or avoid starting levodopa, which is the standard treatment for this condition. In a completed Phase 3 trial called TEMPO-4, most people taking tavapadon long-term did not need to start levodopa, and those already taking it didn't need to increase their dose. This suggests tavapadon could be a helpful new option for managing early Parkinson's symptoms.

WHY IT MATTERSIf approved, tavapadon could allow people with early Parkinson's to delay levodopa therapy, potentially postponing side effects that come with long-term use of this standard medication.
💬 Ask your doctorParkinson's disease

Get personalized rare disease news

Follow your conditions to see news about the diseases that matter to you — FDA approvals, trial openings, and research breakthroughs.

Create free account →Browse diseases